CEL-SCI Corporation (AMEX:CVM) executed a reverse stock split at a ratio of 30 for 1 on May 20, 2025, aiming to optimize its capital structure.
The reverse stock split led to a significant price drop of approximately 45.02%, indicating the challenges in stabilizing CVM’s stock price.
CVM’s market capitalization stands at approximately $7.52 million, with a trading volume indicating active interest despite recent declines.

CEL-SCI Corporation, trading on the AMEX under the symbol CVM, is a biotechnology company focused on developing immunotherapy treatments for cancer and infectious diseases. On May 20, 2025, CVM executed a reverse stock split at a ratio of 30 for 1. This strategic move is part of CEL-SCI’s efforts to optimize its capital structure and enhance shareholder value.
The reverse stock split, as highlighted by Business Wire, is a significant step for CEL-SCI. It aims to consolidate shares, potentially improving the stock’s market position. Despite this, CVM’s current price is approximately $2.48, marking a substantial decrease of about 45.02% from its previous value. This drop of $2.03 indicates the challenges the company faces in stabilizing its stock price. CVM’s stock has shown volatility, with today’s trading range between a low of $2.32 and a high of $2.60. 
CEL-SCI’s market capitalization is approximately $7.52 million, with a trading volume of 1,266,437 shares. This indicates active trading interest, despite the stock’s recent decline. The reverse stock split is a strategic move to potentially attract more investors by improving the stock’s appeal and market perception.